Company Profile
PTC Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- PTCT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
65.67 USD (-4.78%)
Close
Last updated: November 5, 2026
5.66B USD
Market cap
Why the stock is moving
As of Nov 5, 2026, PTCT closed down 4.78% at $65.67. No new same-company headline was identified in the current news window.
Company overview
Rare-Disease Medicines
PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases.
Commercial Portfolio
Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise. PTC also markets additional rare-disease products in multiple regions.
Vatiquinone
Vatiquinone is an oral small molecule being advanced through a registration study for a rare neurologic disorder following regulatory feedback.
Votoplam
Votoplam is an oral small-molecule splicing modifier under long-term evaluation in Huntington's disease through a collaboration with Novartis.
Future catalysts
- Completion of the ST-920 BLA submission for Fabry disease in the fourth quarter of 2026.
- FDA Type C meeting on votoplam Phase 2 data and a potential accelerated-approval pathway in the first quarter of 2027.
- Potential accelerated approval and U.S. launch of ST-920 in 2027.
- Entry of the MSH3 splicing candidate PTC303 into clinical development in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PTC Therapeutics, Inc. (PTCT)?
PTC Therapeutics, Inc. (PTCT) most recently closed at 65.67 USD, a -4.78% move versus the previous session.
What is the market cap of PTC Therapeutics, Inc. (PTCT)?
PTC Therapeutics, Inc. currently has a market capitalization of 5.66B USD on BioPharmSignal.
What does PTC Therapeutics, Inc. do?
Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise. PTC also markets...
On which exchange is PTCT stock listed?
PTC Therapeutics, Inc. (PTCT) is associated with NASDAQ, United States, Biopharma.
What is ST-920?
Completion of the ST-920 BLA submission for Fabry disease in the fourth quarter of 2026.
Which conditions is PTC Therapeutics, Inc. targeting with ST-920?
PTC Therapeutics, Inc. is associated with metabolic disease based on its company overview and current catalyst commentary.
How does PTC Therapeutics, Inc. describe recent progress with ST-920?
Completion of the ST-920 BLA submission for Fabry disease in the fourth quarter of 2026.
What is Rare-Disease?
Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders.